Magazine Article | March 1, 2023

Why RNA Is Good For Business

Source: Life Science Leader

By Matthew Pillar, Editor, Bioprocess Online

Early last year, Nutcracker Therapeutics landed a $170 million Series C to further its work developing an RNA drug development platform. That’s pretty noteworthy, considering how easy it is for biopharmaceutical companies to get lost in the cacophony of their peer companies rallying around the therapeutic potential of RNA. Hundreds of biotechs around the globe can count at least one RNA-based therapeutic in their development arsenal, if not because the science is promising, almost certainly because the acronym attracts attention from the investment community.

access the Magazine Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Life Science Leader